NCT03031938View on ClinicalTrials.gov

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 3, 2017

Primary Completion Date

June 4, 2020

Study Completion Date

June 4, 2020

Conditions
OsteoarthritisCancer PainRecurrent Low Back Pain
Interventions
DRUG

Investigational medical product (IMP) administered in parent study

IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study

Trial Locations (6)

33609

Pediatric Epilepsy & Neurology Specialists, Tampa

34232

Gulfcoast Research Institute, Sarasota

Kennedy and White Orthopaedic Center, Sarasota

47905

Lafayette Clinical Research Group, Lafayette

Preferred Pediatrics, Lafayette

90033

USC Keck School of Medicine, Los Angeles

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Pfizer

INDUSTRY

NCT03031938 - Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies | Biotech Hunter | Biotech Hunter